韓笑,劉瑩,梁迎春,閆志風(fēng),徐小潔,梁九思,洪甜,尤文葉,陳思禹,黃俊,葉棋濃,劉丹
1.錦州醫(yī)科大學(xué) 附屬第一醫(yī)院,遼寧 錦州 121000;2.解放軍總醫(yī)院,北京 100853;3.軍事醫(yī)學(xué)科學(xué)院 生物工程研究所,北京 100850
人ERK2基因?qū)θ艘暰W(wǎng)膜母細(xì)胞瘤WERI-Rb-1細(xì)胞生長的影響
韓笑1,3,劉瑩1,2,梁迎春3,閆志風(fēng)2,徐小潔3,梁九思1,洪甜3,尤文葉2,陳思禹2,黃俊3,葉棋濃3,劉丹1
1.錦州醫(yī)科大學(xué) 附屬第一醫(yī)院,遼寧 錦州 121000;2.解放軍總醫(yī)院,北京 100853;3.軍事醫(yī)學(xué)科學(xué)院 生物工程研究所,北京 100850
目的:構(gòu)建攜帶Myc標(biāo)簽的人細(xì)胞外信號(hào)調(diào)節(jié)激酶2(ERK2)的真核表達(dá)載體,表達(dá)Myc-ERK2融合蛋白,檢測(cè)其對(duì)人視網(wǎng)膜母細(xì)胞瘤細(xì)胞生長的影響。方法:采用PCR技術(shù)從乳腺文庫中擴(kuò)增人ERK2基因序列,將其插入pXJ-40載體;將重組質(zhì)粒與空載體轉(zhuǎn)染人視網(wǎng)膜母細(xì)胞瘤WERI-Rb-1細(xì)胞系后,Western印跡檢測(cè)表達(dá)情況,并進(jìn)行生長曲線實(shí)驗(yàn)。結(jié)果:雙酶切和測(cè)序鑒定表明Myc-ERK2真核表達(dá)質(zhì)粒構(gòu)建成功;轉(zhuǎn)染W(wǎng)ERI-Rb-1細(xì)胞后融合蛋白獲得表達(dá),生長曲線實(shí)驗(yàn)結(jié)果表明ERK2可促進(jìn)腫瘤細(xì)胞的生長。結(jié)論:攜帶Myc標(biāo)簽的人ERK2基因的真核表達(dá)載體能在人視網(wǎng)膜母細(xì)胞瘤WERI-Rb-1細(xì)胞中表達(dá),且能促進(jìn)該細(xì)胞的生長。本實(shí)驗(yàn)為進(jìn)一步研究ERK2在腫瘤尤其是眼惡性腫瘤中的功能奠定了基礎(chǔ)。
細(xì)胞外信號(hào)調(diào)節(jié)激酶2(ERK2);真核表達(dá);人視網(wǎng)膜母細(xì)胞瘤細(xì)胞
細(xì)胞外信號(hào)調(diào)節(jié)激酶(extracellular signal regulated kinase,ERK)是絲裂原活化蛋白激酶(mitogen-activated protein kinase,MAPK)成員之一[1-2],其N端與C端相互卷曲形成一種典型的雙葉結(jié)構(gòu)的多肽鏈[3]。ERK家族有5個(gè)亞族,即ERK1、ERK2、ERK3、ERK4和 ERK5。對(duì) ERK1和ERK2調(diào)節(jié)不同細(xì)胞內(nèi)的減數(shù)分裂和有絲分裂等一系列生理活動(dòng)的研究比較明確[4]。研究表明,血小板衍生生長因子(platelet derived growth fac?tor,PDGF)能通過ERK1/2信號(hào)通路影響視網(wǎng)膜色素上皮細(xì)胞的增殖和遷移[5]。ERK2還參與信號(hào)通路的激活和腫瘤的發(fā)生發(fā)展,可通過磷酸化底物蛋白調(diào)節(jié)細(xì)胞的生理功能,調(diào)控細(xì)胞周期、增殖、轉(zhuǎn)錄、分化、凋亡、遷移和黏附等功能,在惡性腫瘤的發(fā)生、轉(zhuǎn)移和浸潤等方面起重要作用[4,6]。因此,我們擬構(gòu)建ERK2的真核表達(dá)載體,以便進(jìn)一步研究ERK2與視網(wǎng)膜母細(xì)胞瘤的調(diào)控。
大腸桿菌DH5α、人乳腺文庫、真核表達(dá)載體pXJ-40為本實(shí)驗(yàn)室保存;VigoFect轉(zhuǎn)染試劑、Western印跡發(fā)光檢測(cè)試劑盒購自Vigorous公司;限制性內(nèi)切酶、T4DNA連接酶、PCR相關(guān)試劑購自TaKaRa公司;質(zhì)粒提取試劑盒、PCR產(chǎn)物回收試劑盒、膠回收試劑盒購自Promega公司;新生牛血清購自浙江天杭生物科技有限公司;DMEM購自Gibco公司;胰酶購自Amersco公司;引物由北京賽百盛生物技術(shù)有限公司合成;測(cè)序由北京奧科鼎盛生物技術(shù)有限責(zé)任公司完成。
以人乳腺文庫為模板,根據(jù)NCBI中的ERK2序列合成上游引物(5'-CCCAAGCTTATGGCGGC GGCGGCGGCGGC-3')和下游引物(5'-CCGCTCG AGTTAAGATCTGTATCCTGGCTGGAATC-3'),PCR擴(kuò)增ERK2序列(擴(kuò)增條件:預(yù)變性95℃ 5 min;變性95℃ 30 s,退火 60℃ 30 s,延伸72℃ 50 s,30個(gè)循環(huán);再延伸72℃ 7 min)。使用高保真PfuDNA聚合酶,擴(kuò)增產(chǎn)物于4℃保存,用膠回收試劑盒回收。
用BamHⅠ/HindⅢ雙酶切pXJ-40載體,37℃,4 h,經(jīng)10 g/L瓊脂糖凝膠電泳后,膠回收載體大片段;將PCR片段回收后再用BamHⅠ/HindⅢ雙酶切,暴露出酶切位點(diǎn)的粘性末端,用T4DNA連接酶連接入pXJ-40載體,轉(zhuǎn)化大腸桿菌DH5α,挑選克隆,振蕩培養(yǎng)并提質(zhì)粒,用BamHⅠ/HindⅢ雙酶切鑒定。酶切鑒定正確的克隆送北京奧科鼎盛生物技術(shù)有限責(zé)任公司測(cè)序。
按常規(guī)實(shí)驗(yàn)方法轉(zhuǎn)染。用含雙抗、10%胎牛血清的DMEM培養(yǎng)基將HEK293T細(xì)胞接種于6 cm皿中,接種量以轉(zhuǎn)染時(shí)細(xì)胞密度達(dá)80%為宜,培養(yǎng)24 h后進(jìn)行轉(zhuǎn)染,轉(zhuǎn)染前1 h換液。將4 μL VigoFeet與 200 μL NaCl混合,室溫靜置 5 min,再將總量為10 μg的重組質(zhì)粒Myc-ERK2與200 μL NaCl混合,然后將上述2種溶液輕輕混合,室溫放置15 min,加入6 cm皿中,并以同樣方法轉(zhuǎn)染空載體作為對(duì)照,于37℃、5%CO2細(xì)胞培養(yǎng)箱中培養(yǎng),4~6 h更換為正常DMEM培養(yǎng)液,24 h后收集細(xì)胞,加入RIPA裂解液冰浴30 min,加入等量的2×SDS緩沖液,煮沸15 min,12 000 r/min離心2 min,取上清液進(jìn)行SDS-PAGE后,電轉(zhuǎn)移至硝酸纖維素膜上,用5%脫脂奶粉封閉硝酸纖維素膜,隨后用5%脫脂奶粉以1∶1000稀釋HRP標(biāo)記的抗Myc標(biāo)簽鼠單克隆抗體進(jìn)行孵育,室溫輕搖1 h,TBST洗膜3次,每次5 min;用化學(xué)發(fā)光法顯色5 min,壓片顯影。
將Myc-ERK2和空載體轉(zhuǎn)染W(wǎng)ERI-Rb-1細(xì)胞,48 h后取處于對(duì)數(shù)生長期的細(xì)胞,計(jì)數(shù)后稀釋至2×104/L,分別接種于5個(gè)96孔板,各設(shè)3個(gè)重復(fù)孔,常規(guī)培養(yǎng)。每日取一塊96孔板,在接種孔內(nèi)用排槍加入10 μL CCK-8溶液,37℃放置1~4 h,在波長450 nm處測(cè)定樣品D值。
以人乳腺文庫為模板擴(kuò)增ERK2基因,獲得約1080 bp的PCR產(chǎn)物,與預(yù)期一致(圖1)。
圖1 ERK2基因的PCR產(chǎn)物瓊脂糖凝膠電泳圖
將PCR產(chǎn)物雙酶切后與pXJ-40載體連接,轉(zhuǎn)化大腸桿菌DH5α,挑選陽性克隆提質(zhì)粒進(jìn)行雙酶切鑒定,凝膠電泳可見約1080 bp的條帶(圖2),表明ERK2序列已成功插入Myc標(biāo)簽中。測(cè)序結(jié)果顯示與已知序列完全一致,從而證明重組質(zhì)粒Myc-ERK2構(gòu)建成功。
圖2 Myc-ERK2重組質(zhì)粒酶切瓊脂糖凝膠電泳圖
將構(gòu)建的重組質(zhì)粒Myc-ERK2和空載分別轉(zhuǎn)染HEK293T細(xì)胞,4~6 h后更換為DMEM完全培養(yǎng)液,24 h后提取細(xì)胞蛋白,進(jìn)行SDS-PAGE,
圖3 Western印跡檢測(cè)融合蛋白Myc-ERK2的表達(dá)
圖4 ERK2能促進(jìn)WERI-Rb-1細(xì)胞的生長
為了探討WERI-Rb-1細(xì)胞中ERK2活性對(duì)其增殖是正調(diào)控還是負(fù)調(diào)控,用CCK8試劑盒檢測(cè)ERK2對(duì)WERI-Rb-1細(xì)胞生長的影響。結(jié)果證明ERK2能促進(jìn)WERI-Rb-1細(xì)胞的生長(圖4)。Western印跡檢測(cè)Myc-ERK2蛋白的表達(dá)。結(jié)果顯示,轉(zhuǎn)染重組質(zhì)粒Myc-ERK2后,在相對(duì)分子質(zhì)量約43 000處可見明顯的特異性條帶,而轉(zhuǎn)染空載體后則無條帶,表明重組蛋白Myc-ERK2能在HEK293T細(xì)胞中正確表達(dá)(圖3)。
視網(wǎng)膜母細(xì)胞瘤(retinoblastoma,RB)是一種起源于視網(wǎng)膜胚胎性的眼內(nèi)惡性腫瘤,多發(fā)于嬰幼兒,發(fā)病率為1∶15 000,近年來仍有逐漸上升趨勢(shì)。血-視網(wǎng)膜屏障(blood-retina barrier,BRB)由內(nèi)層BRB(inner BRB,IBRB)及外層BRB(outer BRB,OBRB)組成,在維持視網(wǎng)膜內(nèi)環(huán)境穩(wěn)定方面起非常重要的作用[7-9]。ERK是一類絲/蘇氨酸蛋白激酶[10],ERK通路在MAPK通路中起重要作用。MAPK通路由Ras/Raf/MEK/ERK通路組成,其信號(hào)的傳導(dǎo)遵循MAKP的三級(jí)聯(lián)體系,即MAPK、MAPK激酶(MAPK kinase,MAPKK)、MAPKK激酶(MAPKK kinase,MAPKKK),激活順序依次為:MAPKKK激活MAPKK,MAPKK激活MAPK,活化后的MAPK進(jìn)入細(xì)胞核,導(dǎo)致細(xì)胞核內(nèi)轉(zhuǎn)錄的激活[11-12]。研究表明,阻斷小鼠體內(nèi)ERK信號(hào)傳導(dǎo)通路,可以減少缺氧條件下OBRB的被破壞[13]。視網(wǎng)膜缺血和再灌注廣泛參與眼部疾病,引起視網(wǎng)膜神經(jīng)節(jié)細(xì)胞(retinal ganglion cell,RGC)死亡,導(dǎo)致視覺障礙和失明[14]。Gao等研究發(fā)現(xiàn),p-ERK蛋白抑制ERK活性上調(diào)對(duì)缺血性腦損傷和損傷RGC有明顯的保護(hù)作用[15]。同時(shí),ERK通路的異常與惡性腫瘤的發(fā)生發(fā)展也密切相關(guān)。研究表明ERK2的活化可改變細(xì)胞病理性增殖,雌激素可通過對(duì)ERK2通路的影響來抑制動(dòng)脈平滑肌細(xì)胞的增殖[16]。在腎臟中,ERK2通路參與急性腎衰竭的炎癥反應(yīng)可導(dǎo)致腎小管上皮細(xì)胞凋亡增加和炎性標(biāo)記物增加[17]。在乳腺癌中,ERK2的過表達(dá)促進(jìn)細(xì)胞增殖和抑制細(xì)胞凋亡[18]。在肝癌中,ERK2的活化和過表達(dá)可增強(qiáng)肝癌細(xì)胞的遷移能力[19]。因此,研究ERK2有助于明確腫瘤細(xì)胞的增殖和凋亡機(jī)制及對(duì)腫瘤發(fā)生發(fā)展的影響,進(jìn)而指導(dǎo)腫瘤的治療和新藥的研制。
[1]Kurioka T,Matsunobu T,Satoh Y,et al.ERK2 medi?ates inner hair cell survival and decreases susceptibili?ty to noise-induced hearing loss[J].Sci Rep,2015,5:16839.
[2]Costa A P,Lopes M W,Rieger D K,et al.Differen?tial activation ofmitogen-activated protein kinases,ERK 1/2,p38(MAPK)and JNK p54/p46 during post?natal development of rat hippocampus[J].Neurochem Res,2016,41(5):1160-1169.
[3]Karapetsas A,Giannakakis A,Pavlaki M,et al.Bio?chemical and molecular analysis of the interaction be?tween ERK2 MAP kinase and hypoxia inducible fac?tor-1αInt[J].J Biochem Cell Biol,2011,43(11):1582-1590.
[4]Buscà R,Christen R,Lovern M,et al.ERK1 and ERK2 present functional redundancy in tetrapods de?spite higher evolution rate of ERK1[J].BMC Evol Bi?ol,2015,15:179.
[5]Hochmann J,Sobrinho J S,Villa L L,et al.The Asian-American variant of human papillomavirus type 16 exhibits higher activation of MAPK and PI3K/AKT signaling pathways,transformation,migration and inva?sion of primary human keratinocytes[J].Virology,2016,492:145-154.
[6]Zumsande M,Gross T.Bifurcations and chaos in the MAPK signaling cascade[J].J Theor Biol,2010,265(3):481-491.
[7]Sengupta T K,Talbot E S,Scherle P A,et al.Rapid inhibition of interleukin-6 signaling and Stat3 activa?tion mediated by mitogen-activated protein kinases[J].Proc Natl Acad Sci USA,1998,95(19):11107-11112.
[8]Eblen S T,Slack J K,Weber M J,et al.Rac-PAK signaling stimulates extracellular signal-regulated ki?nase(ERK)activation by regulating formation of MEK1-ERK complexes[J].Mol Cell Biol,2002,22(17):6023-6033.
[9]Al-Hussaini H,Kilarkaje N.Effects of diabetes on ret?inal pigment epithelial cell proliferation and mitogenactivated protein kinase signaling in dark Agouti rats[J].Exp Toxicol Pathol,2015,67(2):117-124.
[10]Furukawa Y,Okuyama S,Amakura Y,et al.Isolation and characterization of activators of ERK/MAPK from citrus plants[J].Int J Mol Sci,2012,13(2):1832-1845.
[11]Asati V,Mahapata D K,Bharti S K.PI3K/Akt/mTOR and Ras/Raf/MEK/ERK signaling pathwaysinhibitors as anticancer agents:structural and pharmacological per?spectives[J].Eur J Med Chem,2016,109:314-341.
[12]昌毓穗,劉季春,傅華群,等.Ras/Raf/MEK/ERK通路在食管癌藥物靶向治療中的作用[J].藥學(xué)學(xué)報(bào),2013,48(5):635-641.
[13]Xin L,Ma X,Xiao Z,et al.Coxsackievirus B3 induc?es autophagy in HeLa cells via the AMPK/MEK/ERK and Ras/Raf/MEK/ERK signaling pathways[J].Infect Genet Evol,2015,36:46-54.
[14]Fei F,Li J,Rao W,et al.Upregulation of homer1a promoted retinalganglion cell survival after retinal ischemia and reperfusion via interacting with Erk path?way[J].Cell Mol Neurobiol,2015,35(7):1039-1048.
[15]Gao S,Andreeva K,Cooper N G.Ischemia-reperfu?sion injury of the retina is linked to necroptosis via the ERK1/2-RIP3 pathway[J].Mol Vis,2014,20:1374-1387.
[16]Ulm S,Liu W,Zi M,et al.Targeted deletion of ERK2 in cardiomyocytes attenuates hypertrophic re?sponse but provokes pathological stress induced cardi?ac dysfunction[J].J Mol Cell Cardiol,2014,72:104-116.
[17]Wang S,Wei Q,Dong G,et al.ERK-mediated sup?pression ofcilia in cisplatin-induced tubular cell apoptosis and acute kidney injury[J].Biochim Biophys Acta,2013,1832(10):1582-1590.
[18]Youn B,Kim H D,Kim J.Nm23-H1/nucleoside di?phosphate kinase as a key molecule in breast tumor angiogenesis[J].Expert Opin Ther Targets,2008,12(11):1419-1430.
[19]Liu X,Luo F,Ling M,et al.MicroRNA-21 activation of ERK signaling via PTEN is involved in arsenite-in?duced autophagy in human hepatic L-02 cells[J].Toxi?col Lett,2016,252:1-10.
Effect of HumanERK2Gene on Growth of Human Retino?blastoma WERI-Rb-1 Cells
HAN Xiao1,3,LIU Ying1,2,LIANG Ying-Chun3,YAN Zhi-Feng2,XU Xiao-Jie3,LIANG Jiu-Si1,HONG Tian3,YOU Wen-Ye2,CHEN Si-Yu2,HUANG Jun3,YE Qi-Nong2*,LIU Dan1*
1.The First Affiliated Hospital of Jinzhou Medical University,Jinzhou 121000;2.Chinese PLA General Hospital,Beijing 100853;3.Beijing Institute of Biotechnology,Beijing 100850;China
Objective:To construct the eukaryotic expression vector of human extracellular signal regulated ki?nase 2(ERK2) labeled with Myc and detect its expression and activity in human retinoblastoma cells.Methods:Human ERK2 coding region was amplified from human mammary cDNA library by PCR and cloned into pXJ-40 vector.The recombinant plasmid Myc-ERK2 was transfected into human WERI-Rb-1 cells and the expression was detected by Western blot.The proliferation of WERI-Rb-1 cells was examined by growth curve experiment.Results:Myc-ERK2 eukaryotic expression vector was constructed and verified by double enzyme digestion and nu?cleic acid sequencing.Human ERK2 protein was expressed in human WERI-Rb-1 cells as was shown by West?ern blot results and ERK2 protein promoted the proliferation of WERI-Rb-1 cells.Conclusion:The Myc-ERK2 was identified to promote WERI-Rb-1 cell proliferation,which is a fundamental study for ERK2's role in retinob?laastoma.
human extracellular signal regulated kinase 2(ERK2);eukaryotic expression;human retinoblastoma cells
Q78
A
1009-0002(2017)05-0610-04
10.3969/j.issn.1009-
*Co-corresponding authors,LIU Dan,E-mail:docliu61@163.com;YE Qi-Nong,E-mail:yeqn66@yahoo.com
2017-04-27
國家自然科學(xué)基金(81672602,81472589,81502264);北京市科技新星計(jì)劃(Z141102001814055);軍事醫(yī)學(xué)科學(xué)院創(chuàng)新基金轉(zhuǎn)化醫(yī)學(xué)項(xiàng)目(ZHYX003)
韓笑(1989- ),女,碩士研究生,(E-mail)hanxiao9910@sina.com;劉瑩(1981- ),女,博士研究生,(E-mail)liuying5322@163.com;梁迎春(1979- ),女,博士研究生,(E-mail)lyc.513@163.com;三者為共同第一作者
劉丹,(E-mail)docliu61@163.com;葉棋濃,(E-mail)yeqn66@yahoo.com